Introduction {#s1}
============

Thiazide diuretics (TZD) are one of the most widely prescribed therapeutic agents for treatment of hypertension and are also used in the treatment of heart failure and stroke ([@B131]). However, the mechanism underlying chronic reduction of arterial pressure to TZD remains unclear despite investigations over greater than five decades. It is widely agreed that decreased total peripheral vascular resistance underlies TZD chronic pressure reduction ([**Table 1a**](#T1){ref-type="table"}). Moreover, an extrarenal target for TZD action has been proposed ([**Table 1a**](#T1){ref-type="table"}). However, there is little consensus on the extrarenal TZD target responsible for the chronic reduction of arterial pressure. Proposals range widely from indirect mechanisms, in which TZD inhibit regulatory sites upstream from the vasculature, to TZD direct inhibition of vascular constriction ([**Table 1a**](#T1){ref-type="table"}).
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Likely contributing to the wide range of proposed TZD targets for chronic reduction of arterial pressure and, furthermore, largely overlooked, are the use of the following:

1.  1\) Hypertensive models that are sensitive and insensitive to TZD arterial pressure reduction. In this regard, TZD reduce arterial pressure in some hypertensive patients, while TZD lack efficacy in others, i.e., "responders" and "nonresponders," respectively ([**Table 1b**](#T1){ref-type="table"}). Indeed, as great as 20% of hypertensive patients are resistant to TZD arterial pressure reduction (Dudenbostel et al., 2017). Similarly, models of hypertension can be sensitive (1 kidney/DOCA-salt, 1 kidney/DOCA, DOCA-salt, angiotensin II-salt, spontaneous hypertensive rats, dietary salt in rats, NO synthase inhibitor, *cyp1a1-Ren2* hypertensive rats, capsaicin-high salt, and low renin hypertension) or insensitive (renal, e.g., following renal artery constriction; neurogenic/sympathetic nervous system, e.g., following aortic depressor plus sinus nerve ligation and vagi-aortic nerve ligation, increased dietary salt in mice, angiotensin II, and hyperaldosteronism) to TZD arterial pressure reduction ([**Table 1c**](#T1){ref-type="table"}). Indeed, overall predictors of greater responsiveness to TZD include lower levels of plasma renin and urine aldosterone ([@B35]). Clearly, the efficacy of TZD and other antihypertensive agents to reduce arterial pressure depends upon the target sites in the different types of hypertension ([@B78]).

2.  2\) Normotensive subjects and animals. TZD fail to reduce arterial pressure in normotensive subjects/animals ([**Table 1d**](#T1){ref-type="table"}; [**Figure 1**](#f1){ref-type="fig"}).

3.  3\) Acute TZD challenge. Contrasting mechanisms underlie TZD acute and chronic reduction of arterial pressure, with the former renal mediated, caused by diuresis and accompanying decreased plasma volume, and the latter in which arterial pressure reduction and plasma volume depletion are dissociated ([**Table 1a**](#T1){ref-type="table"}; [**Figure 1**](#f1){ref-type="fig"}).

4.  4\) Supra-therapeutic dose/concentration of TZD. At therapeutic dose, TZD selectively inhibit the Na^+^/Cl^−^ cotransporter (NCC; *SLC12A3*; [@B163]). NCC, which is expressed on the apical membrane of distal convoluted tubule cells, is the renal target responsible for TZD diuresis ([**Table 1e**](#T1){ref-type="table"}). However, at supra-therapeutic dose, TZD also inhibit the a) Na^+^-dependent chloride--bicarbonate exchanger (NDCBE; *SLC4A8*; [**Table 1f**](#T1){ref-type="table"}). NDCBE, which is located on the basolateral membrane of medullary collecting duct cells, regulates cell pH ([@B192]) and b) carbonic anhydrase isozymes ([@B168]). Carbonic anhydrase isoenzymes are located in the renal proximal tubule and intercalated cells, where they mediate bicarbonate transport, as well as extrarenally ([@B168]). Also, a number of *in vivo* studies on the effects of TZD on arterial blood pressure and a large majority of *in vitro* studies of the effects of TZD on the vasculature generally utilized supra-therapeutic TZD concentrations \[(Na+/Cl^−^Cotransporter (NCC; SLC1283), *In Vivo* TZD on Vascular Contractility Determined In Vitro\].

![Time course of thiazide diuretic effects on arterial pressure, plasma volume, diuresis, and levels of angiotensin II/renin, ENaC, and pendrin in hypertension in responders and normotension. Acute through chronic time course of thiazide diuretic (TZD) effects in normotension (top panel) and hypertension (bottom panel) on relative changes in arterial pressure (**^\_\_.\_\_^**), plasma volume (**^...^**), renin activity/angiotenisn II and aldosterone plasma levels (**^\_\_\_\_\_^**), diuresis (\-\-\--), and epithelial sodium channel (ENaC) and pendrin expression (**^\_\_..^**)**^.^** Features of the time course include **(1)** plasma volume: decreased with acute TZD and partial return to pre-TZD level with chronic TZD, with similar magnitude and time course in normotension and hypertension; **(2)** arterial pressure: reduced with acute and chronic TZD in hypertension and unaffected in normotension despite similar changes in plasma volume and diuresis; **(3)** renin activity/angiotensin II and aldosterone plasma levels: increased with acute and chronic TZD. Angiotensin II/renin and aldosterone levels in normotension with TZD have not been measured (to our knowledge) and, therefore, are speculated based upon the decreased plasma volume; and **(4)** ENaC and pendrin expression: increased with acute and chronic TZD, with similar magnitude and time course in normotension and hypertension. Increased ENaC and pendrin expression likely compensate for the Double-headed arrows indicate variable effects. TZD-induced diuresis mediated through NCC inhibition. Only single time points for ENaC and pendrin have been reported, and thus, the time course is speculative. Double-headed arrows indicate variable effects. See text for additional details.](fphar-10-00815-g001){#f1}

This review 1) comprehensively describes findings related to TZD reduction of arterial pressure; 2) differentiates between observations derived from TZD-sensitive and TZD-insensitive hypertensive models, normotensive subjects/animals, acute and chronic TZD, and TZD dose/concentration; 3) proposes guiding parameters for clinically relevant, extrarenal TZD target identification; 4) critically evaluates proposed TZD extrarenal targets; and 5) proposes a working model for TZD chronic reduction of arterial pressure through dilation of the vasculature.

(1) Dose/Concentration of TZD {#s1_1}
-----------------------------

The use of supra-therapeutic doses/concentrations in *in vivo* and *ex vivo* studies undoubtedly contributes to the lack of clarity regarding the mechanism of TZD chronic reduction of arterial pressure. In order to clarify this potential impact, it is important to initially establish the values which constitute supra-therapeutic TZD doses/concentrations.

### Therapeutic TZD Doses/Concentrations {#s1_1_1}

TZD doses exceeded those required for maximal efficacy in early years of TZD use ([@B170]). Subsequently, TZD doses were substantially decreased in order to lower the incidence of side effects, with the overwhelming majority of TZD doses established at less than *p.o*. 50 mg/day (approximately 0.65 mg/kg/day; [@B122]; [@B170]; [@B184]).

Bioavailability of TZD varies from 65% to 95% ([@B170]). Treatment of hypertension with *p.o.* hydrochlorothiazide 7.5--25 mg/day (approximately 0.1--0.3 mg/kg/day) resulted in a median plasma concentration of 0.26 µM ([@B160]). Consistent with the plasma hydrochlorothiazide level derived at these doses ([@B160]), treatment of hypertension and congestive heart failure with *p.o.* 75 mg/day (approximately 1 mg/kg/day) and 50 mg/day (approximately 0.7 mg/kg/day), respectively, yielded peak blood levels of approximately 1--3 µM ([@B19]; [@B20]; [@B21]).

(2) Diuresis and Plasma Volume {#s1_2}
------------------------------

Fundamental to TZD reduction of arterial pressure and, thus, elucidation of the TZD extrarenal target, is increased diuresis and resultant decreased plasma volume. Characteristics of TZD-induced diuresis and decreased plasma volume include differentiation into acute and chronic phases and associated underlying mechanisms.

### Responders and TZD-Sensitive Hypertension Models {#s1_2_1}

Acute TZD reduction of arterial pressure correlates with diuresis and the associated decreased plasma volume in hypertensive humans and animals ([**Table 1g**](#T1){ref-type="table"}; [**Figure 1**](#f1){ref-type="fig"}). Exceptions to this correlation are TZD pressure reduction prior to decreased plasma volume ([@B74]; [@B80]; [@B105]).

Plasma volume repletion reversed acute TZD reduction of arterial pressure, consistent with the correlation between acute arterial pressure reduction and diuresis ([**Figure 1**](#f1){ref-type="fig"}). Specifically, after TZD treatment for 6 days, dextran infusion increased arterial pressure as well as the cardiac index and reduced total peripheral vascular resistance in humans ([@B56]). However, after TZD treatment for 7 days, in which the plasma volume decrease was maintained at the initial reduced level, plasma and saline infusion did not alter arterial pressure ([@B90]). Also, in barbiturate-anesthetized 1 kidney/DOCA hypertensive rats challenged with TZD for 5--8 days, hypotonic saline and dextrose infusion did not reverse the reduced arterial pressure, although hypertonic saline infusion increased systolic pressure, albeit not diastolic pressure ([@B50]).

In contrast to acute TZD, chronic TZD reduction of arterial pressure appears dissociated from diuresis and decreased plasma volume ([**Figure 1**](#f1){ref-type="fig"}). With respect to diuresis, TZD chronic reduction in arterial pressure is maintained while diuresis is minimized in hypertensive humans ([**Table 1h**](#T1){ref-type="table"}). TZD also did not alter serum Na^+^ ([**Table 1h**](#T1){ref-type="table"}). Additionally, water and Na^+^ balance returned to normal during TZD challenge of hypertensive high Na^+^ diet/angiotensin II rats and spontaneously hypertensive rats, while reduced arterial pressure was maintained ([@B15]; [@B94]). Also consistent with the dissociation between diuresis and chronic TZD reduction of arterial pressure is the lesser diuretic efficacy of TZD than inhibitors of the luminal Na--K--Cl cotransporter (NKCC2) located in the thick ascending limb of Henle (loop diuretics), i.e., the NCC and NKCC2 regulate approximately 7% and 25% of Na^+^ absorption, respectively (Glover and O'Shaughnessy, 2013), while the antihypertensive efficacy of TZD was greater than that of NKCC2 inhibitors ([@B9]; [@B12]; [@B88]). Contributing to the minimal diuresis is increased expression of epithelial Na^+^ channel (ENaC) and Na^+^ anion exchanger, pendrin ([@B123]; [@B8]; [**Figure 1**](#f1){ref-type="fig"}).

With respect to plasma volume, TZD-decreased plasma volume apparently returned to pre-TZD level despite continuous TZD for 1--12 months in hypertensive humans ([**Table 1i**](#T1){ref-type="table"}; [**Figure 1**](#f1){ref-type="fig"}). Whether, in fact, plasma volume completely or only partially returned to pre-TZD level is unclear because a number of these studies demonstrated a tendency for reduced plasma volume. Moreover, the magnitude of plasma volume return to pre-TZD level may be overestimated by increased hemoglobin ([@B86]; [@B101]). Along these lines, the TZD lowered plasma volume only partially returned at 2--3 months of TZD treatment ([@B190]; [@B83]), and as determined at a single time point during TZD treatment, plasma volume was decreased at 12 and 24 months of TZD ([@B109]; [@B172]; [@B51]).

Also consistent with the only partial return of plasma volume with chronic TZD is the return of TZD-reduced arterial pressure following plasma volume expansion with dextran plus saline or glucose infusion at 2 weeks to 8 months of TZD treatment in hypertensive humans ([@B189]). In partial agreement, following 2 weeks to 9 months of TZD treatment, dextran plus glucose infusion resulted in partial return of systolic pressure while the decreased diastolic pressure remained ([@B190]).

Additionally, plasma volume repletion with elevated dietary Na^+^ reversed TZD chronic reduction of arterial pressure in hypertensive humans ([@B188]). At 6 days post single TZD injection (*i.v*. 1 g of chlorothiazide), increased dietary Na^+^ of 140 mEq/day (1.8 g/day) from previously lowered 9 mEq/day (0.2 g/day), completely reversed the sustained reduction of arterial pressure to pre-TZD level ([@B188]). In partial agreement, greater amounts of dietary Na^+^ salt, i.e., 6--12 g/day (2.4--4.8 g/day Na^+^) only partially reversed TZD-mediated arterial pressure reduction, and complete reversal required 20 g/day (8 g/day Na^+^; [@B68]; [@B188]; [@B65]; [@B190]). Also, following withdrawal of TZD, plasma volume increases ([@B189]; [@B172]).

Apparently inconsistent with the correlation between elevated Na^+^ and reversal of TZD-reduced arterial pressure, TZD reduction of arterial pressure remained despite prevention of Na^+^ loss by mineralocorticoid co-administration ([@B90]). However, it is likely that TZD-decreased plasma volume was actually maintained because weight loss, an indirect measure of plasma volume, also remained following mineralocorticoid co-administration ([@B90]).

Decreased Na^+^ excretion as the result of Na^+^-restricted diet (urinary excretion from 3.75 g Na^+^/day to 2 g Na^+^/day) which was associated with reduced arterial pressure and increased renin activity and aldosterone plasma level, also failed to prevent further arterial pressure reduction by TZD in the absence or presence of angiotensin receptor antagonists in humans ([@B145]; [@B183]; [@B186]). The TZD arterial pressure reduction was still associated with plasma volume contraction because Na^+^-restricted diet did not prevent TZD-increased Na^+^ excretion (urine volume not reported) and futher increased plasma renin activity and aldosterone levels ([@B145]; [@B183]).

### Summary and Conclusions: Responders and TZD-Sensitive Hypertension Models {#s1_2_2}

Among the findings in support of an extrarenal, vascular mechanism mediating TZD chronic reduction of arterial pressure in hypertensive humans and animals is the maintained pressure reduction despite return of plasma volume towards pre-TZD levels ([**Figure 1**](#f1){ref-type="fig"}). Overall, however, it appears that a remaining component of TZD acute decreased plasma volume is required for chronic TZD reduction in arterial pressure ([**Figures 1**](#f1){ref-type="fig"}, [**2**](#f2){ref-type="fig"}). Thus, TZD chronic reduction of arterial pressure is dependent upon decreased plasma volume both as a trigger for the subsequent maintained arterial pressure reduction and for its ability to sustain the reduction ([**Figure 2**](#f2){ref-type="fig"}).

![*Working model of effects of thiazide diuretics on vascular constriction and arterial pressure.* **(A)** Normotensive subjects: thiazide diuretics (TZD) induce diuresis but fail to reduce arterial pressure. The lack of pressure reduction results from a balance between vasoconstriction due to (1) signaling pathways activated in response to TZD decrease in plasma volume and (2) TZD direct inhibition of the vasoconstriction. **(B)** Normotensive subjects and decreased plasma Na^+^: vasoconstriction due to activation of compensatory regulatory pathways in response to decreased plasma Na^+^ by Na^+^-restricted diet plus TZD-induced diuresis is unable to mitigate the reduction in arterial pressure caused by TZD direct inhibition of the constriction. **(C)** TZD-sensitive hypertension: TZD reduce arterial pressure due to TZD direct inhibition of vasoconstriction overcoming constriction due to both plasma volume contraction (in response to decreased plasma volume) and hypertension. **(D)** TZD-insensitive hypertension: TZD fail to reduce arterial pressure due to inhibition of diuresis, plasma volume contraction, and/or prevention of TZD inhibition of vascular constriction (circled 1, 2, and 3, respectively). See text for additional details.](fphar-10-00815-g002){#f2}

### Normotensive Humans and Animals {#s1_2_3}

Acute and chronic TZD failed to reduce arterial pressure in normotensive humans and animals despite the diuresis and decreased plasma volume ([**Table 1j**](#T1){ref-type="table"}; [**Figure 1**](#f1){ref-type="fig"}). A supra-therapeutic TZD dose was required to reduce arterial pressure in dogs ([@B143]). Lack of TZD reduction of arterial pressure was not due to decreased diuresis because TZD caused similar magnitudes of changes in Na^+^ and K^+^ per body weight, as well as extracellular fluid volume and serum osmolarity, in normotensive subjects and hypertensive patients ([@B67]; [@B90]; [**Figure 1**](#f1){ref-type="fig"}). Diuresis due to NKCC2 inhibitors was also greater than diuresis due to TZD in normotensive subjects, while NKCC2 inhibitors still failed to reduce arterial pressure ([@B96]).

In apparent contrast to the lack of TZD reduction of arterial pressure in normotensive humans and animals ([**Table 1j**](#T1){ref-type="table"}; [**Figure 1**](#f1){ref-type="fig"}), in hypertensive humans. TZD and Na^+^-restricted diet elicited a steady reduction of arterial pressure ([@B145]). Na^+^-restricted diet did not prevent TZD diuresis and natriuresis in rats ([@B87]) and, thus, were presumably also not prevented in humans.

Although TZD did not cause diuresis in normotensive mice, the absence of diuresis may actually reflect the relatively delayed assessment, i.e., day 3--4 post initial TZD ([@B8]). This suggestion is supported by the return to baseline within 24 and 72 h of increased diuresis due to *p.o*. TZD *q.d*. ([@B72]; [@B39]) and 48 h *p.o*. TZD *b.i.d*. ([@B189]). Also, ENaC and pendrin expression, which presumably compensates for TZD diuresis through increased Na^+^ reabsorption, increased on day 3 post initial TZD treatment (earliest time point assayed; [@B8]; [**Figure 1**](#f1){ref-type="fig"}). Along these lines, diuresis increased 2 h post a single *i.v*. injection of TZD in rats and ENaC activity remained unchanged ([@B70]).

### Summary and Conclusions: Normotensive Humans and Animals {#s1_2_4}

TZD failed to reduce arterial pressure in normotensive humans and animals despite similar magnitudes of diuresis and plasma volume decrease as in hypertensive humans and animals ([**Figures 1**](#f1){ref-type="fig"}, [**2**](#f2){ref-type="fig"}). The lack of TZD reduction of arterial pressure suggests a balance between compensatory contraction of the plasma volume and TZD mitigation of the contracted volume through inhibition of vasoconstriction ([**Figure 2**](#f2){ref-type="fig"}). However, this balance is disrupted by further plasma volume contraction, which can occur, e.g., with increased Na^+^ loss, resulting in TZD reduction of arterial pressure ([**Figure 2**](#f2){ref-type="fig"}).

### Responders versus Nonresponders {#s1_2_5}

TZD-mediated increased diuresis and plasma volume reduction, and body weight loss were greater in responders than nonresponders ([@B51]; [@B66]; [**Table 2**](#T2){ref-type="table"}). Also, TZD failed to decrease plasma volume in a study limited to nonresponders ([@B167]). The greater contracted plasma volume of responders was suggested to underlie increased TZD reduction of total peripheral vascular resistance ([@B51]). Consistent with the lesser magnitude of plasma volume contraction in nonresponders is the lack of angiotensin II and aldosterone plasma level elevation ([@B167]; Constrictor Pathways *In Vivo*, Endogenous Activation; [**Table 2**](#T2){ref-type="table"}). The lesser decrease in plasma volume in nonresponders than responders was not associated with lesser decreases in serum K^+^ ([@B51]; [@B167]).

###### 

Effects of Thiazide Diuretics in Responders and Nonresponders on Physiological and Biochemical Parameters in Hypertension.

  Effect                               Responder vs Non-responder^1^   Reference
  ------------------------------------ ------------------------------- -----------
  NCC ^2^ expression/phosphorylation   \>                              [@B133]
  Diuresis                             \>                              [@B66]
  Plasma volume decrease               \>                              [@B51]
                                       \>                              [@B66]
                                       ≡^3^                            [@B180]
  Weight loss                          ≡                               [@B180]
                                       \>                              [@B66]
  Renin/angiotensin II                 ≡^3^                            [@B180]
                                       ≡^3,4^                          [@B66]
  Aldosterone                          \<                              [@B180]
  Cardiac/sympathetic                  ≡                               [@B51]
                                       \>                              [@B180]

^1^Greater, less, equivalent: \>, \<, ≡; ^2^NCC = Na^+^/Cl^-^ cotransporter; ^3^Tended to be less; ^4^Extrapolation based on equivalent TZD dose.

In contrast, there was a tendency for increased plasma volume contraction in chronic TZD-treated nonresponders than responders ([@B180]; [**Table 2**](#T2){ref-type="table"}). It was suggested that the tendency for greater plasma volume contraction in nonresponders, which was associated with a tendency for greater elevated plasma levels of angiotensin II (Constrictor Pathways *In Vivo*, Endogenous Activation; [**Table 2**](#T2){ref-type="table"}), resulted in increased peripheral vascular resistance ([@B180]) and, thus, diminished TZD-decreased arterial pressure. On the other hand, body weight was not different in responders and nonresponders ([@B180]; [**Table 1**](#T1){ref-type="table"}).

### Summary and Conclusions: Responders versus Nonresponders {#s1_2_6}

The dependency of TZD reduction of arterial pressure upon relaxation of vasoconstriction suggests that the inability of TZD to reduce arterial pressure in nonresponders may reflect the lack of compensatory vasoconstriction ([**Table 2**](#T2){ref-type="table"}; [**Figure 2**](#f2){ref-type="fig"}). That is, the inability of TZD to elicit diuresis results in lack of decreased plasma volume and, therefore, absence of compensatory vasoconstriction ([**Table 2**](#T2){ref-type="table"}; [**Figure 2**](#f2){ref-type="fig"}). This conclusion is supported by the lack of TZD arterial pressure reduction in normotensive humans and animals despite increased diuresis (above). Additionally, lack of diuresis in some types of hypertension associated with nonresponders could result from prevention of diuresis ([**Table 2**](#T2){ref-type="table"}; [**Figure 2**](#f2){ref-type="fig"}).

Alternatively, TZD may induce diuresis in TZD-insensitive hypertension with different etiologies. Thus, the absence of arterial pressure reduction could result from inhibitory effects post plasma volume depletion ([**Figure 2**](#f2){ref-type="fig"}). Additional studies of the effects of TZD in nonresponders with different hypertensive etiologies are warranted, including the mechanism underlying TZD reduction of arterial pressure in nonresponders with co-administration of other antihypertensive agents ([@B153]; [@B170]).

(3) Na^+^/Cl^−^ Cotransporter (NCC; *SLC12A3*) {#s1_3}
----------------------------------------------

Insight into the mechanism underlying TZD chronic reduction of arterial pressure may be derived 1) through the effects of TZD on the activity of NCC, the renal target for TZD diuresis ([**Table 1e**](#T1){ref-type="table"}), and the relationship between NCC activity and arterial pressure in responders and nonresponders; 2) in NCC knockout and NCC/pendrin double-knockout mice ([@B155]; [@B106]; [@B165]; [@B7]); and 3) in humans with dysfunctional NCC, i.e., Gitelman's syndrome ([**Table 1l**](#T1){ref-type="table"});.

### NCC Activity Determinations {#s1_3_1}

NCC activity determinations include increased NCC expression and phosphorylation, with the latter an indicator of NCC trafficking ([@B77]; [@B133]). These two measurements may be unrelated because phosphorylation can be dissociated from increased NCC expression ([@B70]). TZD binding to NCC, determined by high-affinity binding with ^3^H-metolazone ([@B17]), has also been used as an indirect measure of NCC expression and, thus, activity ([@B36]; [@B121]). However, even though TZD increased NCC binding, transport was reduced ([@B121]). Additional potential complications with binding studies include the inability to account for NCC isoforms along with selective isoform phosphorylation ([@B179]; [@B133]), as well as the influence of Na^+^ and Cl^−^ concentrations ([@B17]; [@B176]).

### Responders {#s1_3_2}

In responders, chronic TZD increased NCC expression and NCC phosphorylation, as assayed in urinary vesicular exosomes ([@B133]).

### Normotensive Animals {#s1_3_3}

Acute and chronic TZD increased NCC expression and phosphorylation in whole kidney and, in some studies, distal convoluted tubules from normotensive rats and mice (Northern and Western blot, *in situ* hybridization, and immunohistochemistry; [@B107]; [@B123]; [@B129]; [@B70]). TZD also increased ^3^H-metolazone high-affinity binding to NCC in kidney membrane fractions from normotensive rats ([@B36]; [@B121]).

Enhanced delivery of Na^+^ to the distal collecting duct likely underlies the increased NCC expression ([@B133]) because furosemide, a diuretic that acts through inhibition of NKCC2, also increased NCC expression and binding in rat kidney ([@B36]; [@B123]). Also, angiotensin receptor antagonists failed to increase NCC expression and phosphorylation even though arterial pressure was reduced to a similar magnitude as TZD ([@B133]).

### Responders versus Nonresponders {#s1_3_4}

TZD-induced NCC expression and phosphorylation were greater in responders than nonresponders, as determined in urinary vesicular exosomes ([@B133]; [**Table 1**](#T1){ref-type="table"}).

### Summary and Conclusions: Responders, Normotensive Animals, and Responders versus Nonresponders {#s1_3_5}

Increased NCC expression and phosphorylation due to TZD are consistent with the greater amount of diuresis in responders than nonresponders ([@B66]; [**Table 2**](#T2){ref-type="table"}; [**Figure 2**](#f2){ref-type="fig"}; Diuresis and Plasma Volume). In normotensive animals, there is also a positive relationship between TZD-mediated NCC expression/phosphorylation and diuresis (Diuresis and Plasma Volume). NCC activation is restricted to agents that increase Na^+^ delivery to the distal collecting duct.

### NCC Knockout and NCC/Pendrin Double-Knockout Mice {#s1_3_6}

NCC knockout mice demonstrated changes similar to those observed in Gitelman's syndrome, in which NCC is dysfunctional (below), including hypomagnesemia, hypocalciuria, and increased renin expression (determined in the kidney; [@B155]; [@B106]; [@B7]). It should be noted, however, that TZD increased NCC expression and that NCC expression is decreased in Gitelman's syndrome ([@B95]; [@B92]; [@B193]; [@B70]). This difference in NCC expression with TZD and Gitelman's syndrome may reflect different mechanisms whereby TZD inhibit NCC activity ([@B134]) and of NCC dysfunction in Gitelman's syndrome ([@B149], [@B150]; [@B185]).

Plasma bicarbonate levels were also elevated in NCC knockout mice, indicative of underlying, compensated alkalosis ([@B106]). Additionally, aldosterone plasma levels were elevated ([@B106]), although elevated aldosterone plasma levels were not consistently observed ([@B155]).

Basal arterial pressure: Basal arterial pressure was not significantly decreased in NCC knockout mice, although there was a tendency for decreased arterial pressure ([@B155]). The absence of hypotension in NCC knockout mice was attributed to compensation of mildly decreased intravascular volume ([@B155]; [@B106]; [@B7]). Lack of hypotension in NCC knockout mice ([@B155]; [@B106]; [@B7]), but hypotension in 50% of Gitelman's syndrome patients ([@B48]; below), may reflect differences in Na^+^ handling in mice and humans. This suggestion is supported by the arterial pressure reduction with Na^+^-restricted diet still containing 77.5% of normal in humans ([@B145]), but the absence of arterial pressure reduction by more severe Na^+^-restricted diet of 0.01% and 0.1% in wild-type mice ([@B155]; [@B7]).

In contrast, arterial pressure was lower in NCC knockout mice with Na^+^-restricted diet (0.01% or 0.1%; [@B155]; [@B7]). Thus, it appears that compensatory vasoconstrictor pathways were unable to fully normalize the lower arterial pressure in NCC knockout mice subjected to Na^+^-restricted diet despite further increased renin expression ([@B155]; [@B7]). Similarly, NCC/pendrin double-knockout mice, which demonstrated severe diuresis and natriuresis along with even greater renin expression, was associated with further reduced arterial pressure ([@B165]).

TZD on arterial pressure: Hydrochlorothiazide failed to reduce arterial pressure in NCC knockout mice, despite *s.c.* administration at the supra-therapeutic dose of 20 mg/kg, i.e.*,* approximately 30-fold greater than the therapeutic dose ([@B7]; Dose/Concentration of TZD). In fact, 20 mg/kg of hydrochlorothiazide would result in a plasma concentration of approximately 50 µM (Dose/Concentration of TZD). Lack of hydrochlorothiazide reduced arterial pressure in NCC knockout mice may reflect conditions similar to those associated with normotensive subjects and animals ([**Figure 2**](#f2){ref-type="fig"}). That is, vasoconstriction available for TZD relaxation is minimal due to the relatively small magnitude of decreased intravascular volume and, thus, minimal compensatory vasoconstriction ([**Figure 2**](#f2){ref-type="fig"}).

In contrast, hydrochlorothiazide (20 mg/kg) reduced arterial pressure in NCC knockout mice subjected to Na^+^-restricted diet ([@B7]). Moreover, in NCC/pendrin double-knockout mice, hydrochlorothiazide elicited an even greater reduction in arterial pressure than in NCC knockout mice subjected to Na^+^-restricted diet ([@B7]). Thus, the magnitude of hydrochlorothiazide arterial pressure reduction correlated with greater underlying vasoconstriction as the result of increased intravascular volume depletion ([@B165]; [@B7]; [**Figure 2**](#f2){ref-type="fig"}). Consistent with this suggestion is that prevention of intravascular volume depletion with increased dietary Na^+^ from 1% to 7% abolished both the lowered basal arterial pressure and TZD reduction of arterial pressure in NCC/pendrin double-knockout mice ([@B7]).

It was suggested that TZD reduction of arterial pressure in the absence of NCC provided evidence for an extrarenal TZD target ([@B7]). Further, hydrochlorothiazide arterial pressure reduction does not appear mediated by decreased plasma volume, due to decreased plasma Na^+^ ([@B7]). This conclusion is based upon the finding that urine production was actually decreased in NCC/pendrin double-knockout mice ([@B7]). The decreased urine production was attributed to lowered kidney perfusion with reduced arterial pressure ([@B7]). Also contributing to the decreased urine production was lowered water intake ([@B7]). Inexplicably, food intake was greatly decreased by hydrochlorothiazide ([@B7]).

Measurements of plasma Na^+^ would further test whether decreased plasma volume through lowered plasma Na^+^ was involved in hydrochlorothiazide reduction of arterial pressure in NCC knockout mice subjected to Na^+^-restricted diet and NCC/pendrin double-knockout mice ([@B7]). In this regard, hydrochlorothiazide increased Na^+^ excretion in NCC knockout mice ([@B102]; [@B58]). Furthermore, the increased Na^+^ excretion by hydrochlorothiazide appears mediated through inhibition of the Na^+^-driven chloride--bicarbonate exchanger (NDCBE; *SLC4A8e*; [@B187]; [@B124]; [@B192]) because increased Na^+^ excretion, at least at 50 mg/kg i.p. hydrochlorothiazide, was absent in NCC/NDCBE double-knockout mice ([@B102]; [@B58]; [@B59]; [@B163]).

It should also be considered that the hydrochlorothiazide dose that reduced arterial pressure in the absence of NCC ([@B7]) yields a plasma concentration in the range that inhibits NDCBE. That is, hydrochlorothiazide doses that increased Na^+^ excretion in NCC knockout mice, *i.p.* hydrochlorothiazide 4 and 50 mg/kg ([@B102]; [@B58]), correspond to plasma concentrations of at least 10 and 100 µM, respectively (Dose/Concentration of TZD). In fact, the hydrochlorothiazide concentration used in the metabolic studies in NCC/pendrin double-knockout mice, 40 mg/kg, would yield a plasma concentration of approximately 100 µM ([@B7]; Dose/Concentration of TZD). Further, 100 µM hydrochlorothiazide inhibited NDCBE in perfused renal cortical collecting ducts of mice ([@B102]). In comparison, the IC~50~ for metolazone inhibition of Na^+^ uptake by NCC was 2 or 0.3 µM (depending upon the report; [@B152]; [@B119]). Also, essentially complete inhibition of NCC by metolazone occurred at 10 µM ([@B152]; [@B119]).

On the other hand, 10 mg/kg i.p. hydrochlorothiazide was selective for NCC as demonstrated in STE20/SPS1-related proline/alanine-rich kinase (SPAK)-dead knock-in mice ([@B77]). Specifically, in SPAK-dead knock-in mice, which demonstrated decreased NCC expression and phosphorylation leading to overall decreased NCC activity, hydrochlorothiazide saliuresis was absent ([@B146]; [@B77]). Although NKCC2 expression and phosphorylation were also decreased in SPAK-dead knock-in mice ([@B146]; [@B77]), saliuresis to the loop diuretic, furosemide, was not decreased ([@B146]; [@B77]). However, whether NDCBE function is also decreased in SPAK-dead knock-in mice is not known (to our knowledge).

Although a lowered IC~50~ for TZD inhibition due to increased NDCBE expression following NCC knockout ([@B58]) could occur, depending upon the presence of NDCBE spare transporters, a lowered IC~50~ does not appear to occur at least in Gitelman's syndrome. In support of this conclusion is the decreased Na^+^ and Cl^−^ excretion with a single therapeutic dose of hydrochlorothiazide (*p.o.* 50 mg; [@B45]; [@B135]; below).

While NDCBE-mediated TZD reduction of arterial pressure in NCC knockout mice subjected to Na^+^-restricted diet and NCC/pendrin double-knockout mice ([@B7]) may occur through hyponatremia, it should also be considered that hyponatremia may not accompany increased Na^+^ excretion. However, TZD-induced hyponatremia has been associated with decreased NCC ([@B34]). In fact, hyponatremia was observed in approximately one of seven TZD-treated patients ([@B76]; [@B26]). Further, in patients with demonstrated hyponatremia treated with hydrochlorothiazide plus amiloride, challenge with 50 mg of hydrochlorothiazide, albeit combined with 5 mg of amiloride, caused hyponatremia ([@B69]).

A major caveat, however, with respect to the potential functional role of NDCBE in Na^+^ handling and, therefore, possible high dose TZD-induced saliuresis and/or natriuresis, is the location of NDCBE within the kidney. Specifically, it was suggested that NDCBE was located in β-intercalated cells of the cortical collecting duct, consistent with saliuersis/natriuresis regulation ([@B187]; [@B124]). In direct contrast, we were unable to locate NDCBE in cortical collecting duct β-intercalated cells ([@B192]). Moreover, NDCBE was restricted to the basolateral membrane of the medullary collecting duct ([@B192]), thereby questioning the potential role of NDCBE in Na+ handling.

### Summary and Conclusions: NCC Knockout and NCC/Pendrin Double-Knockout Mice {#s1_3_7}

TZD reduction of arterial pressure in NCC knockout mice subjected to Na^+^-restricted diet, but not NCC knockout mice with normal Na^+^ diet, and an even greater pressure reduction in NCC/pendrin double-knockout mice ([@B7]) are consistent with the dependency of TZD reduction of arterial pressure on decreased plasma volume *per se* and associated compensatory vasoconstriction (Diuresis and Plasma Volume; [**Figure 2**](#f2){ref-type="fig"}). Thus, the considerable diuresis associated with less reduction of arterial pressure with NKCC2 inhibitors compared with TZD ([@B189]; [@B9]; [@B12]; [@B88]; Diuresis and Plasma Volume) would reflect unopposed compensatory vasoconstriction with the NKCC2 inhibitors.

However, while TZD-reduced arterial pressure in NCC knockout mice with Na^+^-restricted diet and an even greater pressure reduction in NCC/pendrin double-knockout mice are suggestive of an extrarenal TZD target, an involvement of hyponatremia due to NDCBE inhibition cannot be completely eliminated because of the use of supra-therapeutic TZD dose ([@B7]). In fact, lack of TZD reduction of arterial pressure in Gitelman's syndrome (below) at least indirectly supports the possibility of NDCBE inhibition in TZD reduction of arterial pressure. Overall, however, considering that NDCBE is apparently located on the basolateral membrane of medullary collecting duct ([@B192]) rather than in β-intercalated cells of the cortical collecting duct ([@B187]; [@B124]), the function of NDCBE in response to hydrochlorothiazide needs to be revisited.

### Gitelman's Syndrome {#s1_3_8}

Gitelman's syndrome is an autosomal recessive malady attributed to dysfunctional NCC, largely due to missense mutations ([@B149]; [@B150]; [@B185]). These mutations result in undetectable or reduced NCC amounts in urinary exosomes ([@B95]; [@B92]; [@B193]). Consistent with NCC dysfunction in Gitelman's syndrome is the lesser increase in urinary excretion of Na^+^ and Cl^−^ to hydrochlorothiazide (single, therapeutic dose of *p.o.* 50 mg; [**Table 1k**](#T1){ref-type="table"}; Dose/Concentration of TZD). In contrast, urinary excretion of Na^+^ and Cl^−^ increased in response to furosemide (loop diuretic; *i.v.* bolus infusion of 40 mg in [@B45] and *i.m.* 20 mg in [@B136]).

The phenotype associated with Gitelman's syndrome includes hypomagnesemia, hypocalciuria, hypochloremia, and hypokalemic alkalosis ([**Table 1I**](#T1){ref-type="table"}; mimicked by NCC knockout mice; [@B155]; [@B7]; above). Vascular volume depletion is also associated with Gitelman's syndrome, which results in elevated plasma renin levels/activity and aldosterone levels ([@B177]; [@B162]). Hypotension occurs in approximately 50% of patients with Gitelman's syndrome (62% and 12% of patients and control subjects, respectively; [@B48]). Based on measurements in neutrophils and monocytes from patients with Gitelman's syndrome, the hypotension and absence of hypertension despite elevated plasma renin levels/activity and aldosterone levels were attributed to up-regulation/down-regulation of signaling pathways that would result in decreased vasoconstriction and basal vascular tone ([@B32], [@B31]; [@B33]). These signaling pathways include decreased inositol trisphosphate release of intracellular Ca^2+^, decreased activation of protein kinase C, increased nitric oxide formation due to increased endothelial nitric oxide synthase expression, inhibition of oxidation signaling mechanisms (which mediate vasoconstriction to angiotensin II and other constrictors), decreased G-protein coupling through reduced α~q~ expression, decreased agonist activation of Rho kinase through down-regulation of RhoA/Rho kinase signaling, and increased heme-oxygenase-1 expression ([@B32], [@B31]; [@B33]).

However, possibly inconsistent with the predicted decreased agonist constriction and/or basal vascular tone in patients with Gitelman's syndrome ([@B32], [@B31]; [@B33]) are 1) autonomic function was preserved in hypotensive, Gitelman's syndrome patients ([@B154]). Autonomic function was determined indirectly by reflex tests including the Valsalva maneuver, cold pressor, hand grip, and hyperventilation and by norepinephrine and arginine vasopressin plasma levels in response to the reflex tests ([@B154]). And 2) basal blood flow in the forearm of two hypotensive patients with Gitelman's syndrome did not differ from basal blood flow in normotensive and hypertensive subjects ([@B140]).

Also, possibly inconsistent with the potential extrarenal TZD target in NCC knockout mice subjected to Na^+^-restricted diet and in NCC/pendrin double-knockout mice ([@B7]), in two patients with Gitelman's syndrome with 8 and 25 µg hydrochlorothiazide/min/dL forearm infusion (plasma hydrochlorothiazide concentrations of 2.7 and 11.0 µM, respectively), blood flow did not increase ([@B140]). Similarly, while 75 µg hydrochlorothiazide/min/dl infusion (38 µM of hydrochlorothiazide) increased forearm blood flow in Gitelman's syndrome patients, the magnitude of increase was not different from the increased blood flow in normotensive and hypertensive subjects ([@B140]). The increased blood flow to 75 µg hydrochlorothiazide infusion likely resulted from non-specific effects to the approximately 20-fold greater than therapeutic plasma levels of hydrochlorothiazide ([@B140]; Dose/Concentration of TZD).

Additionally, based upon the acute hydrochlorothiazide reduction of arterial pressure in NCC knockout mice subjected to Na^+^-restricted diet and in NCC/pendrin double-knockout mice ([@B7]; above), TZD may have been predicted to reduce arterial pressure in patients with Gitelman's syndrome. However, hydrochlorothiazide infusion into the forearm also did not reduce arterial pressure in the two Gitelman's syndrome patients (as well as the normotensive and hypertensive subjects; [@B140]). The limited duration of hydrochlorothiazide infusion, i.e., 5 min, however, may have been insufficient to determine whether arterial pressure was actually reduced ([@B140]). Arterial pressure was also not reduced following diagnostic challenge with *p.o.* 50 mg of hydrochlorothiazide in Gitelman's syndrome patients (L Chen and G Colussi, personal communications), with heart rate also remaining unchanged (G Colussi, personal communication). Lack of hydrochlorothiazide arterial pressure reduction in patients with Gitelman's syndrome appeared independent of basal arterial pressure, as hydrochlorothiazide failed to reduce arterial pressure in Gitelman's syndrome patients with low-normal mean arterial blood pressures, ranging at basal from 73 to 96 mmHg (*n* = 5; G Colussi, personal communication).

On the other hand, plasma volume depletion in patients with Gitelman's syndrome may be insufficient to demonstrate TZD reduction of arterial pressure, consistent with the inability of TZD to reduce arterial pressure in NCC knockout mice with normal Na^+^ diet ([@B7]). However, significant plasma volume depletion likely occurs in Gitelman's syndrome based on the elevated plasma renin levels/activity and aldosterone levels ([@B177]; [@B162]). Further, treatment of Gitelman's syndrome, a condition associated with high Na^+^ intake, includes *ad libitum* dietary Na^+^ ([@B23]). Despite the increased Na^+^ intake, the intake apparently is insufficient to fully compensate for the decreased plasma volume (Diuresis and Plasma Volume) and, therefore the contribution of the decreased plasma volume to the hypotension.

### Summary and Conclusions: Gitelman's Syndrome {#s1_3_9}

Compensation of contracted plasma volume in Gitelman's syndrome appears to occur through elevated aldosterone and renin and possibly other vasoconstrictor pathways ([@B162]). Hypotension associated with Gitelman's syndrome, along with lack of hypertension despite increased renin activity and aldosterone plasma levels ([@B162]), suggest both an incomplete compensation and a prevention of increased constriction due to reduced vascular contractility ([@B32], [@B31]; [@B33]). However, unaltered autonomic nervous system regulation of arterial blood pressure and absence of changes in basal and TZD-mediated forearm blood flow in patients with Gitelman's syndrome ([@B140]; [@B154]) do not appear to support a mechanism whereby up-regulation or down-regulation of these non-selective vascular inhibitory and excitatory signaling pathways, respectively, underlies hypotension and inhibition of anticipated elevated arterial pressure due to apparent activation of the renin--angiotensin II--aldosterone pathway ([@B32], [@B31]; [@B33]).

Thus, it is tempting to conclude that selective inhibition of the renin--angiotensin II--aldosterone pathway underlies the compromised vascular constriction. This conclusion appears consistent with lower plasma renin and urine aldosterone levels as predictors of greater TZD efficacy of arterial pressure reduction ([@B35]; Diuresis and Plasma Volume). A further speculation is that alterations in blood electrolytes and pH associated with Gitelman's syndrome, i.e., hypomagnesemia, hypocalciuria, hypochloremia, and hypokalemic alkalosis ([**Table 1l**](#T1){ref-type="table"}), underlie possible compromised renin--angiotensin II--aldosterone pathway. However, it appears that these conditions do not decrease the formation of angiotensin II ([@B177]).

The absence of TZD reduction of arterial pressure in Gitelman's syndrome is not supportive of an extrarenal TZD target suggested by TZD reduction of arterial pressure in NCC knockout mice subjected to Na^+^-restricted diet and in NCC/pendrin double-knockout mice ([@B7]). However, this apparent lack of support could be explained if intravascular volume contraction is less in Gitelman's syndrome than in knockout mice models (above).

(4) Constrictor Pathways *In Vivo* {#s1_4}
----------------------------------

### (a) Endogenous Activation {#s1_4_1}

An additional assessment of contracted plasma volume in response to TZD is determination of compensatory constrictor pathways. Moreover, TZD may inhibit the compensatory vasoconstriction, eliciting reduced vascular tone and resulting in only partial compensation of the arterial pressure reduction. Additionally, these same constrictor pathways may be activated in some types of hypertension. Thus, determination of the effects of TZD on these constrictor pathways is fundamental to the identification of the TZD extrarenal target. The involvement of constrictor pathways can be assessed in part through determinations of endogenous levels of humoral and neurogenic constrictor factors and effects of TZD on constriction by these factors. Major compensatory constrictor pathways include the renin--angiotensin II--aldosterone and autonomic nervous systems. Overall, however, the relevance of plasma renin activity and angiotensin II plasma levels is unclear due to the importance of intrarenal versus systemic levels of these factors ([@B148]).

### Renin--Angiotensin II--Aldosterone System {#s1_4_2}

#### Responders and TZD-Sensitive Hypertension Models {#s1_4_2_1}

A varied relationship exists between TZD-induced changes in renin activity/angiotensin II levels in plasma and reduction in arterial pressure ([**Figure 1**](#f1){ref-type="fig"}). In hypertensive patients, chronic TZD-mediated increased renin activity/angiotensin II levels were maintained, partially maintained, or returned to levels not significantly different from pre-TZD levels ([**Table 1m**](#T1){ref-type="table"}).

However, conclusions that chronic TZD failed to elevate renin activity/angiotensin II levels are complicated by the underlying varied relationship between hypertension and plasma renin activity ([@B4]; [@B14]). An additional complication is the inclusion of a significant number of patients on additional antihypertensive medications, although acute TZD increased renin activity despite inclusion of multi-antihypertensive-treated patients ([@B25]). The detection of increased renin activity with acute but not chronic TZD may reflect a greater increase in the former ([@B25]). In the additional study that demonstrated a lack of increased renin activity/angiotensin II levels with chronic TZD, the patient population could be divided into those with and those without elevated plasma angiotensin II levels ([@B191]). Arterial pressure was not reported, and, thus, possible association between TZD arterial pressure reduction and plasma angiotensin II levels remained unexamined ([@B191]). Similar to elevated renin activity/angiotensin II levels in response to TZD, Na^+^-restricted diet also increased renin expression/angiotensin II levels in humans ([@B108]; [@B141]).

TZD-induced changes in aldosterone plasma levels generally correlated with increased renin activity/angiotensin II plasma levels ([**Figure 1**](#f1){ref-type="fig"}). This correlation is based, however, upon a limited number of measurements of aldosterone plasma levels with and, for that matter, without renin activity/angiotensin II plasma levels in response to TZD. In fact, aldosterone levels tended to be elevated and were not significantly elevated when renin activity/angiotensin II levels were increased at 5 weeks and 3 months TZD treatment in humans, respectively ([@B113]; [@B104]). Further, renin activity/angiotensin II levels were at baseline at 2 months TZD treatment ([@B25]; [@B191]). Similarly, aldosterone levels in the urine were not elevated following 3 days to 2 months of treatment with TZD ([@B74]).

Enhanced TZD reduction of arterial pressure occurred with angiotensin receptor antagonists and angiotensin-converting enzyme inhibitor in human and spontaneously hypertensive rat ([**Table 1**](#T1){ref-type="table"}p), as well as with a mineralocorticoid receptor antagonist in human ([@B90]).

#### Normotensive Humans and Animals {#s1_4_2_2}

Renin activity/angiotensin II and aldosterone plasma levels in normotensive humans in response to TZD are largely unreported. Consistent with TZD-increased renin activity/angiotensin II levels, juxtaglomerular granularity increased following 9 weeks' treatment with TZD in rat ([@B175]). Na^+^-restricted diet also increased renin expression/angiotensin II levels in humans and NCC knockout mice and elevated Na^+^ diet decreased angiotensin II levels in humans ([@B73]; [@B7]).

Based upon the similar changes in plasma volume in responders and normotensive humans ([@B67]; [@B90]; Diuresis and Plasma Volume), it is predicted that TZD increased renin activity/angiotensin II levels, as well as aldosterone levels, will be similar to those of responders ([**Figure 1**](#f1){ref-type="fig"}). Na^+^-restricted diet increased aldosterone levels in humans ([@B73]).

#### Responders versus Nonresponders {#s1_4_2_3}

TZD tended to increase renin activity/angiotensin II and aldosterone plasma levels to a greater magnitude in nonresponders than responders ([@B180]; [@B66]; [**Table 2**](#T2){ref-type="table"}). It was suggested that the lack of arterial pressure reduction was due to compensatory angiotensin II vasoconstriction ([@B180]; [@B66]). In contrast, TZD failure to increase renin activity and aldosterone levels in nonresponders was also observed ([@B167]), presumably due to underlying compensatory constrictor mechanisms.

### Autonomic Nervous System {#s1_4_3}

#### Responders and TZD-Sensitive Hypertension Models {#s1_4_3_1}

Plasma levels of norepinephrine remained elevated with chronic TZD, consistent with increased sympathetic activity ([@B99]). Also consistent with the increased norepinephrine plasma levels ([@B99]), chronic TZD in hypertensive humans increased cardiac output/rate, although increased cardiac output/rate was also not observed ([**Table 1n**](#T1){ref-type="table"}). However, sympatholytic procedures and agents employed in the past to reduce arterial pressure, i.e., ganglionic blockers, reserpine, and sympathectomy, enhanced or did not prevent TZD arterial pressure reduction ([**Table 1o**](#T1){ref-type="table"}).

#### Normotensive Humans and Animals {#s1_4_3_2}

As in some responders and TZD-sensitive hypertension models ([**Table 1n**](#T1){ref-type="table"}), heart rate was unaltered with chronic TZD in dogs ([@B93]). Reserpine enhanced the arterial pressure reduction due to supra-therapeutic TZD dose in dogs, which would tend not to support the involvement of the sympathetic nervous system ([@B143]). In fact, TZD-lowered catecholamine levels in a number of tissues in dogs and mice suggest TZD-decreased sympathetic activity ([@B144]).

#### Responders versus Nonresponders {#s1_4_3_3}

Similar responses to the Valsalva maneuver of TZD-treated responders and nonresponders do not support a role for autonomic nervous system activity and cardiac output in the differential reduction of arterial pressure ([@B51]; [**Table 2**](#T2){ref-type="table"}). Resting cardiac output remained unchanged in responders and nonresponders ([@B51]), presumably due to compensatory mechanisms. In partial contrast, while acute TZD decreased cardiac output in responders and nonresponders, with chronic TZD cardiac output returned to pre-TZD levels in responders but not in nonresponders ([@B180]).

#### Summary and Conclusions: Endogenous Activation {#s1_4_3_4}

Increased renin activity/angiotensin II and norepinephrine plasma levels in hypertensive humans and animals are consistent with a remaining component of decreased plasma volume in response to chronic TZD ([**Figure 1**](#f1){ref-type="fig"}). Thus, TZD-reduced arterial pressure, while due to inhibition of compensatory angiotensin II and norepinephrine vasoconstriction as well as presumably other compensatory constrictor pathways, is also mitigated by further compensatory vasoconstriction ([**Figure 2**](#f2){ref-type="fig"}). Additionally, increased renin activity/angiotensin II plasma levels by Na^+^-restricted diet suggest that similar constrictor pathways mediate the compensatory vasoconstriction due to plasma volume reduction in response to lowered Na^+^ and chronic TZD plasma volume decrease. Furthermore, the lesser magnitude of elevated renin activity/angiotensin II plasma levels in nonresponders ([**Table 2**](#T2){ref-type="table"}) is consistent with the lack of plasma volume decrease and resultant absence of arterial pressure reduction.

It should be noted, however, that increased renin activity/angiotensin II levels in response to chronic TZD were not consistently observed in hypertensive humans and animals ([**Figure 1**](#f1){ref-type="fig"}). Furthermore, renin activity/angiotensin II levels were not consistently greater in responders than nonresponders ([**Table 2**](#T2){ref-type="table"}). Clearly, the limited number and contrasting findings of renin activity/angiotensin II levels, as well as aldosterone levels, warrant additional studies.

The enhancement or lack of prevention of TZD arterial pressure reduction by angiotensin receptor antagonists and angiotensin-converting enzyme inhibitor ([**Table 1p**](#T1){ref-type="table"}), mineralocorticoid receptor antagonists ([@B90]), and ganglionic blockers, reserpine, and sympathectomy ([**Table 1o**](#T1){ref-type="table"}) appears inconsistent with TZD reduction of arterial pressure through inhibition of the renin--angiotensin--aldosterone and sympathetic nervous systems. Alternatively, TZD arterial pressure reduction would be enhanced by agents and procedures that disrupt the renin--angiotensin--aldosterone and sympathetic nervous system if TZD only partially inhibit activation of these systems.

The inability of TZD to reduce arterial pressure in neurogenic, i.e., sympathetic nervous system hypertension ([**Table 1c**](#T1){ref-type="table"}), also suggests that TZD inhibition of catecholamine-induced vasoconstriction is not involved in the reduction of arterial pressure. On the other hand, hypertension associated with high but not low renin activity/angiotensin II plasma levels is resistant to TZD reduction of arterial pressure ([@B35]; [**Table 1c**](#T1){ref-type="table"}). The efficacy of TZD to reduce arterial pressure depending upon magnitude of renin--angiotensin II pathway activation may, by analogy, suggest that hypertension associated with high sympathetic nervous system activity is insensitive to arterial pressure reduction.

### (b) Exogenous Agonist {#s1_4_4}

TZD inhibition of the compensatory contracted plasma volume as well as constriction underlying certain types of hypertension may involve direct inhibition of vascular constriction. This assessment can be achieved in part through the effects of TZD on exogenous agonist pressor responses.

Numerous findings describe the effects of acute TZD on agonist-elevated and agonist-reduced vascular bed and mean arterial pressure ([**Table 1q**](#T1){ref-type="table"}). However, based upon the close correlation between acute TZD reduction of arterial pressure and diuresis, the extrarenal-mediated TZD reduction of arterial pressure is most likely absent during acute TZD (Diuresis and Plasma Volume). Thus, findings presented are limited to effects of chronic TZD on pressor responses ([**Table 3**](#T3){ref-type="table"}).

###### 

Effect of Chronic Thiazide Diuretics on Agonist- and Sympathetic Nerve Stimulation-Elevated Arterial Pressure in Normotension and Hypertension.

  ------------------------------------------------------------------------------------------------------------------------------------
  Species   Hypertension          Duration Thiazide Diuretic   Pressure/Flow Measurement   Stimulant         Response^1^   Reference
  --------- --------------------- ---------------------------- --------------------------- ----------------- ------------- -----------
  Dog       No                    7 days                       MAP^2^                      Norepinephrine    ↑             [@B57]

            No                    6--8 weeks                   Hindlimb                    Angiotensin II\   −\            [@B196]
                                                                                           ATP\              −\            
                                                                                           Norepinephrine\   ↓\            
                                                                                           SNS^3^            ↓             

            No                    12 months                    Hindlimb                    Norepinephrine\   −\            [@B93]
                                                                                           SNS               −             

  Human     Essential             8 weeks                      MAP                         Norepinephrine    −             [@B90]

            No                    14 days                      Digital Brachial            Norepinephrine    −, ↑\         [@B117]
                                                                                                             −, ↑          

            No                    7 days                       Forearm                     Norepinephrine    −             [@B62]

            Essential             6 days                       MAP                         Norepinephrine    ↓             [@B5]

            Essential             14 days                      Digital Brachial            Norepinephrine    ↓             [@B117]

  Rat       No                    14 days                      Hindlimb                    Angiotensin II\   −\            [@B10]
                                                                                           Epinephrine\      −\            
                                                                                           Norepinephrine    −             

            No                    7 days                       MAP                         Norepinephrine    −             [@B126]

            Renal^4^              14 days                      Hindlimb                    Angiotensin II\   ↓\            [@B10]
                                                                                           SNS\              ↓\            
                                                                                           Tyramine          −             

            Spontaneous           7 days                       MAP                         Norepinephrine    ↓             [@B126]

            Kidney/DOCA-salt^5^   10 days                      MAP                         Norepinephrine\   −\            [@B63]
                                                                                           SNS\              −\            
                                                                                           Tyramine          −             

            No                    7 days                       MAP                         Angiotensin II\   ↓\            [@B195]
                                                                                           Norepinephrine    ↓             
  ------------------------------------------------------------------------------------------------------------------------------------

^1^↑, ↓, − = increase, decrease, no change; ^2^MAP = mean arterial pressure; ^3^SNS = sympathetic nerve stimulation; ^4^non-responder; ^5^pithed

#### Responders and TZD-Sensitive Hypertension Models {#s1_4_4_1}

In hypertensive patients treated with TZD, norepinephrine pressor responses remained unaltered ([@B90]; [**Table 3**](#T3){ref-type="table"}). In contrast, TZD reduced the norepinephrine increased digital, brachial, and mean arterial pressure ([@B5]; [@B117]; [**Table 3**](#T3){ref-type="table"}) and increased forearm basal flow at supra-therapeutic dose ([@B140]). TZD reduction of mean arterial pressure was independent of hypovolemia because similar magnitudes of TZD reduction of mean arterial pressure occurred in hypovolemic and euvolemic patients ([@B117]). On the other hand, the magnitude of TZD reduction of the norepinephrine pressor response exceeded the magnitude of arterial pressure reduction ([@B117]).

Although not challenged with agonist, venoconstriction due to deep breathing and the Valsalva maneuver decreased in TZD-treated hypertensive patients ([@B130]). These findings are consistent with TZD lowering of neurogenic activity ([@B130]).

The norepinephrine pressor response in spontaneously hypertensive rats was also decreased by TZD ([@B126]; [**Table 3**](#T3){ref-type="table"}). In contrast, TZD did not decrease pressor responses to norepinephrine, tyramine, and sympathetic nerve stimulation in 1 kidney/DOCA-salt hypertensive rats ([@B63]; [**Table 3**](#T3){ref-type="table"}). The differential TZD reduction of agonist pressor response depending upon the agonist ([**Table 3**](#T3){ref-type="table"}; [@B63]; [@B126]) is consistent with the dependency of TZD reduction of hypertension upon the mechanism underlying the hypertension ([@B78]).

#### Normotensive Humans and Animals {#s1_4_4_2}

In normotensive humans, TZD decreased norepinephrine-elevated digital and brachial pressure, although norepinephrine did not consistently elevate pressure ([@B117]). Similarly, norepinephrine decreased forearm blood flow, and TZD increased the flow in Responders and Nonresponders (i.e., reduced the pressure; [@B62]; [**Table 3**](#T3){ref-type="table"}). The TZD-increased flow was attributed to increased cardiac output, possibly as the result of decreased cardioregulatory reflexes ([@B62]).

In support of this suggestion, TZD treatment increased cardiac output and caused lesser decreased heart rate as compared to untreated dogs ([@B57]; [**Table 3**](#T3){ref-type="table"}). TZD also further increased norepinephrine elevated mean arterial pressure ([@B57]; [**Table 3**](#T3){ref-type="table"}). Thus, it was suggested that desensitization of carotid sinus and baroreceptor reflexes was responsible for the norepinephrine-induced increased heart rate and cardiac output with chronic TZD, resulting in further elevation of mean arterial pressure ([@B57]; [**Table 3**](#T3){ref-type="table"}). However, a role for decreased cardiac output in chronic TZD reduction of arterial pressure has been discounted (Central Vasomotor Centers).

In dog hindlimb, TZD did not reduce the elevated pressure due to norepinephrine, epinephrine, angiotensin II, and/or sympathetic nerve stimulation ([@B10]; [@B93]; [**Table 3**](#T3){ref-type="table"}). However, tonic, non-sympathetic, neurogenic tone was decreased by chronic TZD ([@B93]; [**Table 3**](#T3){ref-type="table"}). In contrast, also in dog hindlimb, TZD reduced the elevated pressure due to norepinephrine and sympathetic nerve stimulation, but not to angiotensin II and ATP ([@B196]; [**Table 3**](#T3){ref-type="table"}). However, whether TZD actually reduced norepinephrine elevated mean arterial pressure in the dogs was not reported (Zsoter et al., 1907). TZD was without effect ([@B126]) or reduced the norepinephrine, as well as the angiotensin II pressor response in rats ([@B195]; [**Table 3**](#T3){ref-type="table"}). Thus, similar to the different efficacies of TZD to reduce arterial pressure depending upon the type of hypertension ([**Table 1b and c**](#T1){ref-type="table"}), there is varied TZD decrease in agonist pressor response.

#### Responders versus Nonresponders {#s1_4_4_3}

TZD reduced elevated pressure to sympathetic nerve stimulation, angiotensin II, and norepinephrine, but not to tyramine, in the perfused hindlimb of renal hypertensive rats ([@B10]; [**Table 3**](#T3){ref-type="table"}). The relevancy of the reduced pressor responses is unclear because TZD did not decrease mean arterial pressure in renal hypertensive rats ([@B10]; [**Table 3**](#T3){ref-type="table"}).

#### Summary and Conclusions: Exogenous Agonist {#s1_4_4_4}

Varied TZD reduction of norepinephrine-elevated arterial pressure, along with lack of correlation between these reductions and chronic TZD-reduced mean arterial pressure, casts doubt upon the involvement of possible decreased norepinephrine pressor response in arterial pressure reduction. Few, if any, studies determined TZD effects on pressor responses to agonists other than norepinephrine.

(5) Vascular Contractility *In Vitro* {#s1_5}
-------------------------------------

An additional assessment of TZD inhibition of increased tone due to plasma volume reduction and associated with hypertension is TZD inhibition in the isolated vasculature. The direct inhibition of increased tone can be determined by the effects of TZD a) *in vivo* on subsequently isolated vasculature and b) *in vitro* on agonist constriction.

### (a) ***In Vivo*** TZD on Vascular Contractility Determined ***In Vitro*** {#s1_5_1}

#### Responders and TZD-Sensitive Hypertension Models {#s1_5_1_1}

In femoral artery from hypertensive rats due to nitric oxide synthase inhibitor, a 7-week challenge with hydrochlorothiazide, which lowered the elevated arterial pressure, failed to increase acetylcholine-induced relaxation in isolated femoral artery ([@B164]; [**Table 4**](#T4){ref-type="table"}).

###### 

Effect of Thiazide Diuretics *In Vivo* on Vascular Constriction *In Vitro*.

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Species   Preparation      Method      Hyper-tension   Duration Thiazide   Dose Thiazide^1^   Agonist                 Thiazide Effect^2^   Reference
  --------- ---------------- ----------- --------------- ------------------- ------------------ ----------------------- -------------------- -----------
  Dog       Mesenteric a.    Perfused    No              6 months\           10\                Ang II, NE\             −\                   [@B38]
                                                         12 months           10                 N.S.\                   ↑\                   
                                                                                                Ang II, NE N.S.         −                    

  Rabbit    Mesenteric a.\   Isometric   No              3--4 weeks\         ∼5\                NE\                     −\                   [@B196]
            Mesenteric v.\                               6--10 weeks\        ∼15\               NE\                     −^3^\                
            Mesenteric v.                                6--10 weeks         ∼15                NE\                     ↓\                   
                                                                                                Ang II, BaCl~2~, ACh\   −\                   
                                                                                                Pap, ATP                −^4^                 

  Rat       Femoral a.       Isometric   L-NAME          7 weeks             40                 ACh                     −^4^\                [@B164]
                                                                                                                        −\                   
                                                                                                                        −                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------

a., artery; ACh, acetylcholine; Ang II, angiotensin II; N.S., nerve stimulation; NE, norepinephrine; Pap, papaverine.;v., vein.

^1^mg/kg/day po; ^2^↑, ↓, − = increase, decrease, no change; ^3^tended to decrease; ^4^relaxation.

#### Normotensive Animals {#s1_5_1_2}

In mesenteric arterial bed isolated from normotensive dogs, a 10-month challenge with hydrochlorothiazide failed to reduce norepinephrine-, angiotensin II-, and nerve stimulation-elevated perfusion pressure ([@B38]; [**Table 4**](#T4){ref-type="table"}). In possible contrast, in rabbits challenged with hydrochlorothiazide for 6--10 weeks, constriction of mesenteric artery and vein to norepinephrine tended to decrease and decreased, respectively ([@B196]; [**Table 4**](#T4){ref-type="table"}). However, the significance of the reduced norepinephrine constriction is not clear because the vein is a capacitance vessel ([@B196]; [**Table 4**](#T4){ref-type="table"}). Moreover, norepinephrine constriction was not decreased following up to 4 weeks of challenge with hydrochlorothiazide ([@B196]; [**Table 4**](#T4){ref-type="table"}).

### (b) ***In Vitro*** TZD on Vascular Contractility {#s1_5_2}

Numerous studies investigated TZD inhibition of vascular contractility *in vitro* ([**Tables 1r**](#T1){ref-type="table"} and [**5**](#T5){ref-type="table"}). Moreover, a number of these studies, but not all, demonstrated TZD inhibition of constriction ([**Tables 1s**](#T1){ref-type="table"} and [**5**](#T5){ref-type="table"}). Proposed mechanisms underlying the inhibition of vascular contractility include carbonic anhydrase inhibition, increased nitric oxide release, BKCa^2+^ channel activation, decreased extracellular/intracellular Na^+^, decreased sensitization to intracellular Ca^2+^, RhoA and Rho kinase down-regulation, and inhibition of voltage-dependent Ca^2+^ channel activation ([**Table 1s**](#T1){ref-type="table"}).

However, i) supra-therapeutic TZD dose (Dose/Concentration of TZD) was required in a majority of studies to demonstrate inhibition of vasoconstriction ([**Table 5**](#T5){ref-type="table"}). Even though rabbits challenged with hydrochlorothiazide for 7 weeks with the supra-therapeutic dose of 40 mg/kg/day failed to increase acetylcholine relaxation of isolated femoral artery, while incubation of rabbit isolated femoral artery with 100 µM hydrochlorothiazide enhanced acetylcholine relaxation ([@B164]; Vascular Contractility *In Vitro*, *In Vivo* TZD on Vascular Contractility Determined *In Vitro*; [**Tables 4**](#T4){ref-type="table"} and [**5**](#T5){ref-type="table"}). Indeed, the requirement of supra-therapeutic concentrations *in vitro* is similar to findings in humans of TZD-increased forearm blood flow, which required at least 38 µM of hydrochlorothiazide ([@B139]; [@B140]), and in dogs, which required 9--18 times the usual therapeutic dose of chlorothiazide ([@B132]). Concentration--response (inhibition of constriction) curves to TZD were not performed in a number of investigations ([**Table 5**](#T5){ref-type="table"}). Thus, TZD potency in these investigations remains to be established. ii) The magnitude of TZD inhibition of constriction depended significantly upon the TZD ([@B3]). iii) Conclusions regarding mechanism underlying the inhibition apparently depended upon the contractile agent and/or vessel as observed, e.g., with the role of BKCa^2+^ channel inhibition ([@B27], [@B28], [@B29]; [@B40]; [**Table 5**](#T5){ref-type="table"}). iv) *In vitro* effects may differ from *in vivo* effects. For example, the proposal that TZD decreased constriction through BKCa^2+^ channel inhibition based upon *in vitro* findings ([@B40]; [**Table 5**](#T5){ref-type="table"}) is not supported by observations that *i.p*. paxilline, a BKCa^2+^ channel blocker, and a BKCa^2+^ channel/NCC/pendrin in triple-knockout mice did not prevent acute, hydrochlorothiazide reduction of arterial pressure ([@B7]). And v) vessels were not obtained from animals chronically treated with TZD ([**Table 5**](#T5){ref-type="table"}).

###### 

Effect of Thiazide Diuretics *In Vitro* on Vascular Constriction^1^.

                                                                                             Effect on Contractility^2,3^                  
  ---------------------- --------------------- ----------- -------------- --------- -------- ------------------------------ -------------- ---------
  Guinea pig             Mesenteric a.         Isometric   No             NE        none     ↓                              N/A            [@B27]
  NE                     Glib                  N/A         --                                                                              
  NE                     Indo                  N/A         --                                                                              
  NE                     CTX                   N/A         ↓                                                                               
  NE                     -Endo                 N/A         --                                                                              
  KCl                    none                  --          NA                                                                              
  KCl + Ca^2+^           none                  ↓           N/A            [@B28]                                                           
  KCl + Ca^2+^           IBT                   N/A         ↓                                                                               
  NE                     none                  ↓           NA             [@B29]                                                           
  NE                     Apamin                N/A         --                                                                              
  NE                     Glib                  N/A         --                                                                              
  NE                     Phen                  N/A         --                                                                              
  NE                     CTX                   N/A         ↓                                                                               
  NE                     none                  ↓           N/A            [@B139]                                                          
  NE                     CTX                   N/A         ↓                                                                               
  NE + Ca^2+^            KCl                   N/A         ↓                                                                               
                                                                          NE        none     ↓^4^                           N/A            [@B138]
                                                                          NE        CTX      N/A                            ↓              
  Human                  Internal mammary a.   Isometric   Yes^5^         NE        none     ↓                              N/A            [@B3]
  NE                     Glib                  N/A         --                                                                              
  NE                     CTX                   N/A         ↓                                                                               
  KCl                    none                  --          N/A                                                                             
  Mesenteric a.          Isometric             No          NE             none      ↓        N/A                            [@B41]         
  Essential^6^           NE                    none        ↓              N/A                                                              
  Sub- cutaneous a.      Isometric             No          NE             none      ↓        N/A                            [@B27]         
  NE                     Glib                  N/A         --                                                                              
  NE                     Indo                  N/A         --                                                                              
  NE                     CTX                   N/A         ↓                                                                               
  Mouse                  Aorta                 Isometric   No^7^          Phe       none     --                             N/A            [@B7]
  Mesenteric arteriole   Perfused              No^7^       Phe            none      --       N/A                            [@B147]        
  Rabbit                 Aorta                 Isometric   No             NE        none     --                                            [@B49]
  Rat                    Caudal a.             Perfused    No             Ang II    none     --                             N/A            [@B127]
  N.S. + Ang II          none                  --          N/A                                                                             
  N.S.                   none                  --          N/A                                                                             
  None                   none                  --          N/A                                                                             
  Aorta                  Isometric             No          Phen           none      ↓^8^     N/A                            [@B2]; [@B1]   
  No                     Phe                   -Endo       N/A            ↓^8^                                                             
  Spontaneous            KCl + Ca^2+^          none        ↓              N/A       [@B40]                                                 
  KCl + Ca^2+^           L-NNA                 --          ↓                                                                               
  KCl + Ca^2+^           -Endo                 N/A         ↓                                                                               
  KCl + Ca^2+^           CTX                   N/A         --                                                                              
  No                     NE                    none        --             N/A       [@B42]                                                 
  AVP                    none                  --          N/A                                                                             
  Spontaneous            NE                    none        ↓              N/A                                                              
  NE                     -Endo                 N/A         ↓                                                                               
  AVP                    none                  --          N/A                                                                             
  NE                     -Endo                 N/A         ↓                                                                               
  No                     NE                    none        --             N/A       [@B43]                                                 
  NE                     none                  N/A         ↓                                                                               
  Spontaneous            NE                    none        ↓              N/A                                                              
  NE                     -Endo                 N/A         ↓                                                                               
  NE                     L-NNA                 --          N/A                                                                             
  NE                     Indo                  N/A         ↓                                                                               
  KCl + Ca^2+^           none                  ↓           --                                                                              
                                                           No             NE        none     ↓                              N/A            [@B195]
  Ang II                 none                  ↓           N/A                                                                             
  Ang II                 L-NAME                N/A         --                                                                              
  Ang II                 -Endo                 N/A         --                                                                              
  KCl                    none                  --          N/A                                                                             
  BaCl~2~                none                  --          N/A                                                                             
  Femoral a.             Isometric             No          ACh^9^         none      ↑        N/A                            [@B164]        
  L-NAME                 ACh^9^                none        -- ^10^        N/A                                                              
  Portal v.              Isometric             No          KCl + Ca^2+^   none      ↓        N/A                            [@B118]        
  No                     Spontaneous           none        --             N/A       [@B2]                                                  
  Pulmonary a.           Isometric             No          Phe            none      ↓^8^     N/A                            [@B2]          

^1^Adapted and expanded from [@B147].

^2^Constriction unless relaxation noted.

^3^↑, ↓, − = increase, decrease, no change constriction/relaxation.

^4^Substantial and minimal inhibition by hydrochlorothiazide and bendroflumethazide, respectively.

^5^Hypertension, myocardial infarction, hyperlipidemia, treated with several pharmacologic agents.

^6^Treated with angiotensin II receptor antagonist, angiotensin converting enzyme inhibitor, hydrochlorothiazide.

^7^NCC knockout plus Na^+^ restricted diet.

^8^Inhibition requires plasma ([@B2]) or albumin ([@B1]).

^9^Relaxation.

^10^Tended to increase.

a., artery, ACh, acetylcholine; Ang II, angiotensin II; AVP, arginine vasopressin; CTX, charybdotoxin; Endo, endothelium; Glib, glibenclamide; IBT, iberiotoxin; Indo, indomethacin; L-NAME, N^G^-nitro-L-arginine methylester; L-NNA, N~ω~-nitro-L-arginine; NE, norepinephrine; N.S., nerve stimulation; Pap, papaverine; Phenc, phencyclidine; Phe, phenylephrine; TZD, thiazide diuretic; v., vein.

Generally consistent with the dependency of TZD reduction of arterial pressure on altered regulatory protein expression is the minimal and greatly reduced arterial pressure with acute infusion and with 3-day TZD treatment, respectively, in hypertensive, angiotensin II-salt rats ([@B15]). Additionally, TZD inhibition of vasoconstriction was attributed to decreased expression of proteins that sensitize agonist constriction, RhoA and Rho kinase ([@B195]; [**Table 4**](#T4){ref-type="table"}). This conclusion was based in large part on decreased expression of these proteins with TZD challenge of cultured vascular smooth muscle cells ([@B195]). Consistent with these findings is the more recent demonstration that chronic hydrochlorothiazide reduced arterial pressure in the hypertensive 1 kidney/DOCA-salt rat and decreased the associated elevated Rho-kinase (as well as gene expression of markers of remodeling) in the aorta ([@B11]).

On the other hand, decreased Rho-kinase would be expected to inhibit and enhance agonist constriction and relaxation, respectively ([@B125]). However, 1) chronic TZD failed to consistently inhibit constriction and relaxation was not enhanced (Constrictor Pathways *In Vivo*, Exogenous Agonist; Vascular Contractility *In Vitro*, *In Vivo* TZD on Vascular Contractility Determined *In Vitro*; [**Tables 3**](#T3){ref-type="table"} and [**4**](#T4){ref-type="table"}); 2) while Rho-kinase inhibition reduces arterial pressure in rats with normal arterial pressure ([@B52]), chronic (and acute) TZD do not reduce arterial pressure in rat and other animals and in human (Introduction; Diuresis and Plasma Volume; [**Table 1j**](#T1){ref-type="table"} and d, [**Figure 1**](#f1){ref-type="fig"}; unreported in [@B11] is whether hydrochlorothiazide decreased mean arterial pressure in sham operated rats); 3) although hydrochlorothiazide *in vitro* at clinically relevant concentrations decreased Rho-kinase expression and agonist constriction, based upon the varied inhibitory effects of TZD on vasoconstriction *in vitro* as well as the use in many studies of supra-clinical TZD concentrations (Vascular Contractility *In Vitro*, *In Vitro* TZD on Vascular Contractility; [**Tables 1r, s**](#T1){ref-type="table"}, and [**5**](#T5){ref-type="table"}), it is should be considered that inhibition of Rho-kinase activity by TZD is indirect and requires chronic exposure ([@B11]). In contrast, the Rho-kinase inhibitor, fasudil (Y27632), causes direct inhibition ([@B125]) and 4) intrarenal rather than systemic angiotensin II may be the important modulator of vascular contractility ([@B148]; Constrictor Pathways *In Vivo*, Endogenous Activation). Thus, the possible role of decreased Rho-kinase activity in chronic TZD reduction of arterial pressure remains unclear.

#### Summary and Conclusions: Vascular Contractility In Vitro {#s1_5_2_1}

Lack of inhibition of agonist-induced constriction in vessels isolated from animals chronically challenged with TZD and in NCC knockout mice subject to Na^+^-restricted diet and NCC/pendrin double-knockout mice, despite TZD reduction of arterial pressure ([@B38]; [@B164]; [@B147]; [**Table 5**](#T5){ref-type="table"}), suggests that the condition(s) allowing TZD to reduce arterial pressure is absent *in vitro*. Thus, these findings ([@B38]; [@B164]; [@B7]; [@B147]; [**Table 5**](#T5){ref-type="table"}) do not support proposed mechanisms of TZD inhibition of vasoconstriction based upon *in vitro* challenge with TZD (Vascular Contractility *In Vitro*; [**Table 5**](#T5){ref-type="table"}). Indeed, the presence of the TZD target *in vivo*, but not *in vitro*, is consistent with reversal of TZD chronic reduction of arterial pressure with plasma volume repletion (Diuresis and Plasma Volume).

TZD-induced decreased vasoconstriction could occur through inhibition/activation of smooth muscle signaling pathways or requires up-regulation/down-regulation of these pathways. However, it is unlikely that expression of a potential TZD target at least within the vasculature is up-regulated/down-regulated because i) arteries isolated from animals chronically treated with TZD failed to demonstrate decreased constriction and/or increased relaxation ([@B196]; [@B38]; [@B164]; [**Table 3**](#T3){ref-type="table"}); ii) agonist pressor responses were not decreased with chronic TZD in a number of animal and human investigations ([**Table 3**](#T3){ref-type="table"}); iii) differences in phenylephrine constriction were not detected (independent of structural change) in vessels isolated from wild type and both NCC/pendrin double knockout and NCC knockout plus Na^+^ diet-restricted mice ([@B7]; [@B6]; [@B147]; [**Table 5**](#T5){ref-type="table"}); iv) hydrochlorothiazide, at the supra-therapeutic dose of 20 mg/kg, reduced arterial pressure within 1 h (shortest time period examined in unanesthetized mice) in NCC knockout mice subjected to Na^+^-restricted diet and NCC/pendrin knockout mice ([@B7]). It is unlikely that 1 h is sufficient time to significantly alter protein expression. However, a caveat to this conclusion is that hydrochlorothiazide at this dose may reduce arterial pressure through hyponatremia, rather than an extrarenal target ([@B7]; \[Na^+^/Cl^--^ Contransporter (NCC; SLC12A3)\]); and v) chronic TZD *in vivo* with and without additional TZD challenge of vessels isolated from these animals did not inhibit agonist constriction ([@B196]; [@B38]; [@B164]; [**Table 4**](#T4){ref-type="table"}).

An array of mechanisms has been proposed for TZD direct inhibitory effects on vasoconstriction. However, the relevancy of these mechanisms is limited by the procedures adopted for these determinations ("b" above; *In Vitro* TZD on Vascular Contractility). Furthermore, with respect to overall considerations vis-à-vis measurements of vascular contractility---i.e., 1) the use of resistance type vessels rather than conduit vessels 2) the vessels should be derived from vascular beds associated with resistance, and 3) a relatively small change in contractility, which may or may not be detected depending upon measurement sensitivity, underlies a large change in blood flow, i.e., blood flow is proportional to the fourth power of the radius (Poiseulle's law)---these considerations appear largely satisfied through recent video-imaging measurements of changes in diameter in mesenteric arterioles, i.e., resistance vessels ([@B147]). Moreover, the mesenteric vascular bed is relevant to determinations of peripheral vascular resistance and, thus, arterial blood pressure regulation ([@B85]; [@B37]).

(6) Central Vasomotor Centers {#s1_6}
-----------------------------

In addition to peripheral actions of TZD, potential central effects of TZD need to be considered. The relevancy of central effects of TZD is unlikely because central access of TZD following peripheral administration is limited, as demonstrated in patients with various neurological diseases ([@B160]).

### Responders and TZD-Sensitive Hypertension Models {#s1_6_1}

TZD injection into the hypothalamus reduced arterial pressure in spontaneously hypertensive rats ([@B22]). However, in hypertensive patients, TZD was neutral with respect to central systolic pressure ([@B120]; [@B110]; [@B98]; [@B111]).

Direct TZD application to the carotid artery sinus in the presence and absence of norepinephrine and epinephrine failed to reduce arterial pressure in dogs with acute hypertension due to vagi-aortic nerve denervation ([@B143]; [@B144]). Concomitant with the findings related to baroreceptor reflexes ([@B143]; [@B144]), while TZD increased the gain of renal nerve activity and heart rate in spontaneously hypertensive rats, the increase was non-selective in that similar findings were observed with several classes of anti-hypertensive agents ([@B97]).

### Normotensive Animals {#s1_6_2}

TZD did not lower arterial pressure when infused into the carotid artery in a dog preparation with ligated internal and external carotid arteries with and without carotid sinus denervation ([@B144]). Consistent with these findings TZD were without effect on isolated guinea pig and rabbit heart ([@B143]).

### Summary and Conclusions: Central Vasomotor Centers {#s1_6_3}

It is unlikely that TZD act centrally at vasomotor centers to decrease peripheral vascular resistance. Further, the relevance of determinations of TZD effects in normotensive animals is unclear because TZD do not lower arterial pressure in normotensive humans and animals (Diuresis and Plasma Volume).

(7) Other Signaling Pathways Based Upon Genetic Analysis {#s1_7}
--------------------------------------------------------

### Hypertension Responders and Nonresponders {#s1_7_1}

In terms of baseline protein expression in responders and nonresponders, responders had greater mRNA baseline levels of a number of proteins including vasodilator-stimulated phosphoprotein (VASP) and metabolites of the sphingolipid metabolic pathway ([@B178]; [@B157]; [@B151]). It was suggested that increased baseline VASP expression and the sphingolipid metabolic pathway were responsible for TZD efficacy of arterial blood pressure reduction ([@B157]).

### Summary and Conclusions: Other Signaling Pathways Based Upon Genetic Analysis {#s1_7_2}

The involvement of these pathways in TZD reduction of arterial pressure warrants additional investigation. Indeed, it remains unclear whereby, e.g., increased sphingolipid metabolism would result in greater efficacy of TZD reduction of arterial pressure ([@B157]).

(8) Guiding Parameters {#s1_8}
----------------------

Suggested required parameters for relevant investigations into extrarenal TZD target identification include the following:

1.  \(a\) Therapeutic TZD dose/concentration: *In vivo* doses should be in the therapeutic range (Dose/Concentration of TZD). Indeed, higher TZD doses elicit several effects not relevant to TZD mechanism of action at therapeutic dose (Na+/Cl^−^Contransporter \[NCC; *SLC12A3*\]). *In vitro* concentrations should reflect TZD plasma levels (Dose/Concentration of TZD and Vascular Contractility *In Vitro*).

2.  \(b\) Chronic TZD: The extrarenal TZD target is exposed/present with chronic TZD (Diuresis and Plasma Volume and Vascular Contractility *In Vitro*). Thus, the relevancy of acute TZD challenge *in vivo* and *in vitro* is unclear.

3.  \(c\) TZD effect on normal arterial pressure: TZD should not reduce arterial pressure in normotensive animals. This stipulation is derived from the lack of effect of TZD on arterial pressure in normotensive humans and animals (Diuresis and Plasma Volume). Thus, the relevancy of acute TZD challenge on vascular reactivity in normotensive animals and in vascular tissue from normotensive animals is unclear (Constrictor Pathways *In Vivo;* Vascular Contractility *In Vitro*).

4.  \(d\) TZD and hypertension: TZD should reduce arterial pressure in hypertensive models ("responders" in humans; Diuresis and Plasma Volume). Moreover, due to the dependency of TZD reduction of arterial pressure on underlying hypertension, findings should be derived from hypertensive models and from tissues obtained from these models (Diuresis and Plasma Volume; Vascular Contractility *In Vitro*).

5.  \(e\) TZD and NCC: The acute effects of TZD should be mediated through NCC inhibition (\[Na^+^/Cl^−^ Cotransporter (NCC; *SLC12A3*)\]).

6.  \(f\) Other diuretics: The TZD target should not be utilized by non-TZD, e.g., NKCC2 inhibitors (loop diuretics; Diuresis and Plasma Volume).

7.  \(g\) TZD-insensitive hypertension ("nonresponders" in humans): The TZD target should not be exposed/present in hypertensive models insensitive to TZD arterial pressure reduction (Diuresis and Plasma Volume, \[Na^+^/Cl^−^ Cotransporter (NCC; *SLC12A3*)\]; Constrictor Pathways In Vivo).

(9) Perspective {#s1_9}
---------------

### (a) TZD Target Site {#s1_9_1}

It is unlikely that TZD selectively inhibit the presumably different TZD targets associated with each of the multiple types of hypertension sensitive to reduction by TZD ([**Table 1c**](#T1){ref-type="table"}; Introduction). For example, hypertension varies with respect to the magnitudes of sympathetic nerve activity and vascular contractile sensitivity ([**Table 1t**](#T1){ref-type="table"}). Thus, as illustrated in the working model ([**Figure 2**](#f2){ref-type="fig"}), TZD reduction of arterial pressure is unrelated to direct inhibition of a specific constrictor pathway but rather through a common effect that inhibits constriction to multiple pathways. These multiple pathways underlie constriction (1) to TZD-decreased plasma volume (consistent with earlier proposals of [@B171]; [@B68]; [@B56]; [@B172]) and (2) responsible for the numerous TZD-sensitive types of hypertension ([**Table 1c**](#T1){ref-type="table"}; Introduction). Alternatively, a particular pathway sensitive to TZD inhibition, e.g., renin--angiotensin II, could underlie the multiple types of hypertension associated with responders.

In any case, the above proposal suggests that TZD reduction of arterial pressure is mediated by inhibition of underlying compensatory vasoconstrictor pathways ([**Figure 2**](#f2){ref-type="fig"}). Indeed, removal of the compensatory constriction, through repletion of plasma volume by infusion with dextran plus saline/glucose or elevated dietary Na^+^, reversed TZD chronic reduction of arterial pressure ([@B68]; [@B188]; [@B189]; [@B190]). Also consistent with a common TZD target is enhancement of agonist constriction with myogenic tone ([@B61]).

It should also be noted that, despite the potential attractiveness of the suggestion that NCC serves as the extrarenal target underlying TZD chronic arterial pressure reduction based upon the lower arterial pressure in Gitelman's syndrome ([@B33]), this suggestion is inconsistent with restriction of NCC expression to the kidney, i.e., as evidenced by lack of NCC expression and binding in the aorta, as well as the adrenal gland, brain, heart, intestine (large and small), liver, lung, pancreas, placenta, salivary gland, skeletal muscle, spleen, and testis in humans and/or rats ([@B17]; [@B84]; [@B112]).

### (b) TZD Arterial Pressure Reduction {#s1_9_2}

As illustrated in the working model of [**Figures 2A--D**](#f2){ref-type="fig"}:

(**A**) Normotensive subjects/animals: The proposed dependency of TZD arterial pressure reduction on inhibition of compensatory vasoconstrictor pathways (Guiding Parameters (a) Therapeutic TZD dose/concentration) suggests that the absence of TZD reduction of arterial pressure in normotensive subjects and animals (Diuresis and Plasma Volume) is due to complete mitigation by compensatory vasoconstriction of the TZD inhibition of constriction ([**Figure 2A**](#f2){ref-type="fig"}).

(**B**) Decreased plasma volume: In contrast to the lack of TZD reduction of arterial pressure in normotensive subjects/animals, TZD reduced arterial pressure following enhanced plasma volume depletion, as observed in NCC knockout mice subjected to Na^+^-restricted diet and NCC/pendrin knockout mice ([@B7]). Thus, even greater compensatory vasoconstriction is required to limit the decrease in arterial pressure ([@B7]). However, a further decrease in plasma volume due to TZD cannot be fully compensated for by the already enhanced magnitude of compensatory vasoconstriction. The lack of complete mitigation of the plasma volume reduction, therefore, fails to fully compensate for TZD inhibition of vasoconstriction ([**Figure 2B**](#f2){ref-type="fig"}). A caveat to this explanation is the possible mediation of TZD reduction of arterial pressure in NCC knockout mice subjected to Na^+^-restricted diet and NCC/pendrin knockout mice ([@B7]) through NDCBE inhibition (\[Na^+^/Cl^−^ Contransporter (NCC; *SLC12A3*)\]).

(**C**) TZD-sensitive hypertension: Similar to TZD reduction in arterial pressure following enhanced plasma volume depletion ([@B7]), in TZD-sensitive hypertension, the magnitude of constriction due to hypertension plus decreased plasma volume in response to TZD cannot fully mitigate TZD inhibition of constriction ([**Figure 2C**](#f2){ref-type="fig"}). Thus, TZD reduces the elevated arterial pressure ([**Figure 2C**](#f2){ref-type="fig"}). This proposal further suggests, therefore, that reduction of arterial pressure in hypertension requires an underlying component of reduced plasma volume. In this regard, this suggestion is consistent with the reversal of the TZD lowered arterial pressure with plasma volume repletion (Diuresis and Plasma Volume). It should also be considered, however, that a particular pathway sensitive to TZD inhibition, e.g., renin--angiotensin II, could underlie the multiple types of hypertension associated with responders (Guiding Parameters (a) Therapeutic TZD dose/concentration).

(**D**) TZD-insensitive hypertension: Considering the suggested requirement for an underlying component of reduced plasma volume to lower elevated arterial pressure (**C** above), the inability to decrease arterial pressure in some types of hypertension may be due to prevention of contracted plasma volume ([**Figure 2D**](#f2){ref-type="fig"}). The lack of contracted plasma volume is consistent with the greater TZD-increased diuresis, plasma volume reduction, and body weight loss in responders than nonresponders and the inability of TZD to decrease plasma volume in nonresponders ([@B51]; [@B167]; [@B66]; [**Table 2**](#T2){ref-type="table"}; Diuresis and Plasma Volume). Alternatively, the constrictor pathways underlying TZD-insensitive hypertension may overcome the TZD inhibition of constriction ([**Figure 2D**](#f2){ref-type="fig"}).

Clearly, the identity of the extrarenal site of TZD inhibition of vascular tone remains for further investigation. Moreover, this site is presumably active in Gitelman's syndrome. TZD-insensitive hypertensive models should also assist in this identification through delineation of factors in common with, and different from, TZD-sensitive hypertensive models and unique to particular models. Additionally, several genetic signals associated with sensitivity to TZD reduction of arterial pressure have been identified ([@B116]; [@B158]; [@B151]). Whether these or other signals underlie TZD inhibition of vasoconstriction remains for further investigation. Identification of the TZD extrarenal target will provide the basis for conversion of nonresponder to responder and the development of novel antihypertensive therapies acting through this site.
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